Haemonetics Co. (NYSE:HAE) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP trimmed its position in Haemonetics Co. (NYSE:HAE - Free Report) by 82.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,443 shares of the medical instruments supplier's stock after selling 66,500 shares during the period. ExodusPoint Capital Management LP's holdings in Haemonetics were worth $1,128,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank acquired a new stake in shares of Haemonetics during the fourth quarter worth $32,803,000. Groupama Asset Managment purchased a new stake in Haemonetics during the 4th quarter valued at about $19,520,000. Raymond James Financial Inc. acquired a new position in shares of Haemonetics in the fourth quarter valued at about $19,002,000. Thrivent Financial for Lutherans raised its stake in shares of Haemonetics by 14.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock worth $98,716,000 after purchasing an additional 164,111 shares during the last quarter. Finally, Boston Partners lifted its holdings in shares of Haemonetics by 27.5% during the fourth quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier's stock worth $41,485,000 after purchasing an additional 115,506 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HAE has been the topic of several research reports. JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. Barrington Research decreased their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and lowered their target price for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, Needham & Company LLC reduced their price target on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Price Performance

Shares of HAE stock traded down $0.11 on Wednesday, reaching $58.20. 65,334 shares of the company were exchanged, compared to its average volume of 686,652. The company has a market cap of $2.92 billion, a price-to-earnings ratio of 22.74, a P/E/G ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a 1 year low of $55.30 and a 1 year high of $97.97. The business has a 50-day moving average price of $63.27 and a 200 day moving average price of $73.19. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities research analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.